Citations

Clear

1056 citation(s) found for "Sharma, P".

Machine Learning Prediction of Invasivity in Pituitary Adenomas, Beyond Ki-67 Index
Šťastná, Daniela , Mannion, Richard, Sharma, Rishi, Donnelly, Neil P. , Tysome, James Russell , Axon, Patrick

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1819185 Get It

Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression
Gupta, Sounak, Kosari, Farhad , Thapa, Prabin , Murphy, Stephen J, Johnson, Sarah H. , Dashti, Nooshin K. , Tekin, Burak, Dasari, Surendra, Kipp, Benjamin R. , Sharma, Vidit, Shah, Paras H, Orme, Jacob J. , Frank, Igor, Karnes, R Jeffrey, Boorjian, Stephen A, Vasmatzis, George , Cheville, John C, Zarka, Jabra G, Orme, Jacob J , Murphy, Stephen J. , Greipp, Patricia T. , Tekin, Burak , Zarka, Jabra , Sharma, Vidit , Shah, Paras H., Frank, Igor, Karnes, R. Jeffrey, Boorjian, Stephen A. , Cheville, John C.

Mayo Clinic

Am J Clin Pathol | February 26, 2026 | Volume: 165 | Issue: 4 | Pages: No page available

10.1093/ajcp/aqag023 | PMID 41969028 Get It

Abstract Objectives Sarcomatoid urothelial carcinoma (sUC) is associated with poor clinical outcomes. Herein, we evaluated clinicopathologic features (including PD-L1 expression) for institutional cases. Methods Sixty-five patients with sUC treated by radical cystectomy were matched for age, sex, and pathologic stage to 190 patients with pure urothelial carcinoma (UC). Outcomes were evaluated using the Kaplan-Meier method. Immunohistochemistry (IHC) results for tumor-specific PD-L1 expression in sUC were quantified using H-scores (range, 0-300). Cases with constitutive PD-L1 expression (cPD-L1; H-score ≥240) were evaluated for amplification events using fluorescence in situ hybridization (n = 28), mate-pair sequencing (Mpseq; n = 6), RNA sequencing (n = 5), and targeted next-generation sequencing (n = 8). PD-L1 regulatory pathways were evaluated using gene set enrichment analysis in the Cancer Hallmark dataset. Results Most patients with sUC had advanced disease (≥pT2, 62/65, 95%), without significant differences in overall and cancer-specific survival, when matched to pure UC. Median PD-L1 H-scores using different clones were 100 (SP142), 120 (SP263), and 195 (22C3). cPD-L1 was seen in 43% (28/65) of cases of sUC that were enriched for TP53, TERT, and CDKN2A/B alterations. PD-L1 amplification was identified in 7 (of 28, 25%) of these cases. Bionformatics analysis consistently identified IL6-JAK-STAT3 and interferon α/γ signaling in sUC with cPD-L1 expression. Conclusions Our results suggest that cPD-L1 expression in most sUC occurs secondary to IL6-JAK-STAT3 and interferon α/γ signaling. This provides a biologic rationale for evaluating response to immunotherapy in this patient population.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma
Adenocarcinoma, Expert Panel Adjuvant Therapy for Treatment of Locoregional Gastric, Tchelebi, Leila T. , Jin, Zhaohui, Attallah, Joseph, Abood, G., Akselrod, Dmitriy, Codipilly, D. Chamil, Dozois, Eric J. , Hallemeier, Christopher L., Krishan, Jethwa, Kennedy, Timothy, Lee, Percy P., Ling, Diane, Newman, Neil B. , Sharma, Navesh K, Small, William, Russo, Suzanne , Tchelebi, Leila , Jin, Zhaohui , Abood, Gerard, Akselrod, Dmitriy , Anker, Christopher J. , Codipilly, Don C. , Hallemeier, Christopher Leigh , Lee, Percy , Miller, Eric D. , Sharma, Navesh, Small, William , Russo, Suzanne

Mayo Clinic

American Journal of Clinical Oncology | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001309 | PMID 41712927 Get It

Objectives: To summarize recent high-quality trials and provide an update to the original 2022 American College of Radiology Appropriate Use Criteria for Treatment of Locoregional Gastric Adenocarcinoma. This multi-specialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Methods: Using the population, intervention, comparator, outcome, timing, and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II/II trials and select retrospective studies published between 5/1/2020 and 8/1/2025 in the Embase, Medline, and Pubmed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include adjuvant FLOT chemotherapy for localized gastric adenocarcinoma after neoadjuvant FLOT and surgery, poCT or perioperative chemoimmunotherapy for localized gastric adenocarcinoma, adjuvant chemotherapy +/− CRT for localized gastric adenocarcinoma that undergoes upfront surgery, and systemic therapy alone for localized gastric adenocarcinoma in a medically inoperable patient. Conclusions: This updated ARS AUC summary provides guidelines for the multimodality treatment of resectable gastric adenocarcinoma.
Longitudinal Trends in Cardiac Arrest–Related Mortality in Patients With Chronic Obstructive Pulmonary Disease: A Retrospective U.S. Population-Based Study (1999–2023)
Anwar, Saqlain , Jain, Hritvik , Tariq, Muhammad Shayan , Hassan, Ahmad , Tariq, Urooba, Jannat, Aleesha, Chaudhary, Asma , Waqar, Hassan, Ahmed, Zohab, Khan, Hassaan, Ahmed, Raheel, Sharma, Umesh M., Chaudhary, Asma, Waqar, Hassan, Ahmed, Raheel

Mayo Clinic

Cardiology in Review | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001211 | PMID 41711465 Get It

Sudden cardiac arrest (CA) is a leading cause of death in the United States, with coexisting chronic obstructive pulmonary disease (COPD) recognized as an independent risk factor. National trends in mortality among individuals with both conditions remain unclear. Using Centers for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic Research (multiple cause-of-death data, we conducted a retrospective cross-sectional analysis of deaths with International Classification of Diseases, Tenth Revision codes for COPD (J41–J44) and CA (I46). Age-adjusted mortality rates (AAMRs) were calculated and stratified by race, sex, age group, census region, urbanization level, and place of death. Temporal trends were assessed using Joinpoint regression, reporting annual percent change (APC), and average annual percent change. From 1999 to 2023, a total of 853,773 deaths were recorded, with AAMRs declining from 35.48 to 22.77. The decline was steepest from 1999 to 2006 (APC: –2.77), followed by a more gradual reduction through 2021 (APC: –0.84), and a marked acceleration between 2021 and 2023 (APC: –5.52). Males consistently had higher AAMRs than females (35.41 vs 23.32). Racial disparities persisted, with non-Hispanic (NH) White (29.5) and NH Black individuals (28.16) experiencing the highest rates, followed by NH American Indians (26.17), Hispanics (22.2), and NH Asian/Pacific Islanders (17.82). Mortality was also highest in nonmetropolitan areas (31.37) and the Western region (39.68). Notably, home deaths increased following the coronavirus disease 2019 pandemic. Overall, CA-related mortality in individuals with COPD has declined over the past 25 years, with sharper reductions observed in the post-coronavirus disease period. Despite these improvements, persistent and widening disparities underscore the need for targeted interventions in high-risk populations.
Abstract PS4-10-06: Analysis of Adverse Events and Outcomes of Adjuvant Therapies in TNBC as Monotherapy and Combination: Pembrolizumab, Capecitabine, and Olaparib
Raheem, Farah , Alton, Drake, Sharma, S., Murad, B., Harris, W., Terwilliger, E., Garza-Morales, Rodolfo , Batalini, Felipe

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS4-10-06-PS4-10-06

10.1158/1557-3265.sabcs25-ps4-10-06 Get It

Abstract Introduction Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen (ER), progesterone (PR), and HER2 expression. It accounts for ∼15% of breast cancers and is more common in Black women, younger patients, and those with BRCA1 mutations. TNBC carries a poor prognosis with 5-year survival rates of 92% (localized), 66.8% (regional), and 14.3% (metastatic). Patients with high-risk of recurrence can be treated with different adjuvant therapies based on results of 3 trials (capecitabine, pembrolizumab, olaparib), but data on adverse events (AE) on their combination is limited.High-risk, stage II-III TNBC is treated with curative intent using neoadjuvant chemotherapy with pembrolizumab, followed by surgery and radiation. Pembrolizumab, an anti-PD-1 checkpoint inhibitor, was FDA-approved in 2021 based on KEYNOTE-522. This phase III trial showed that pembrolizumab plus chemotherapy significantly improved pathologic complete response (pCR) and event-free survival (EFS). 3-year EFS was 84.5% vs. 76.8% with placebo (HR 0.63); 5-year follow-up confirmed sustained benefit, with OS of 86.6%. Patients achieving pCR had better outcomes, while those with residual disease remained at high risk for recurrence, justifying further adjuvant therapy.In KEYNOTE-522, grade ≥3 treatment-related (AEs occurred in 77.1% receiving pembrolizumab-chemotherapy vs. 73.3% with placebo-chemotherapy. Pembrolizumab was linked to more serious AEs (34.1% vs. 20.1%) and higher discontinuation rates (23.3% vs. 12.3%). Before pembrolizumab, capecitabine was standard of care for TNBC with residual disease, based on the CREATE-X trial (HR 0.52 for OS benefit). Common AEs included hand-foot syndrome, fatigue, and liver enzyme elevation. Notably, KEYNOTE-522 excluded adjuvant capecitabine, and CREATE-X predated the use of pembrolizumab. Olaparib, a PARP inhibitor, was FDA-approved in 2022 for high-risk early TNBC with germline BRCA mutations, based on OlympiA. It improved invasive disease-free and OS. Grade ≥3 AEs included anemia, neutropenia, and fatigue. OlympiA did not include pembrolizumab or capecitabine, limiting insight into optimal sequencing or combination. Currently, no trials compare pembrolizumab, capecitabine, or olaparib directly, nor do they guide how to sequence or combine these therapies. Despite NCCN guidelines allowing combined/sequential use in high-risk patients, real-world safety and outcome data are lacking. This study aims to evaluate and compare the safety and effectiveness of capecitabine, olaparib, pembrolizumab, and their combinations. We will describe AE rates, onset, discontinuation, and dose modifications to inform clinical management and help reduce early termination of effective therapies. Methods We conducted a retrospective observational study across all Mayo Clinic sites. Eligible patients were ≥18 years with early-stage TNBC who initiated adjuvant therapy with capecitabine, pembrolizumab, olaparib, or combinations (capecitabine + pembrolizumab or olaparib + pembrolizumab) from October 2018 to September 2024. Patients with metastatic disease, other active malignancies, or receiving concurrent investigational therapy were excluded. The primary outcomes were incidence and timing of treatment-related AEs. Secondary outcomes included time to AE resolution, immune-related AEs, treatment interruptions/modifications, early discontinuation, and EFS. Time-to-event data will be analyzed using Kaplan-Meier and Cox proportional hazards models. Subgroup analyses by age, DPYD status, regimen, and dosing will be conducted. Data was abstracted from electronic health records and managed using REDCap. Results Data collection is completed. Final analyses are being conducted, and results will be presented at SABCS 2025. Citation Format: R. Garza-Morales, F. Raheem, D. Alton, S. Sharma, B. Murad, W. Harris, E. Terwilliger, F. Batalini. Analysis of Adverse Events and Outcomes of Adjuvant Therapies in TNBC as Monotherapy and Combination: Pembrolizumab, Capecitabine, and Olaparib [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-10-06.
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer
Grier, Abby , Zhong, Mr Jeffrey, Basourakos, Spyridon P. , Singh, Parminder, Zakharia, Yousef , Lucien, Fabrice , Karnes, R. Jeffrey, Sharma, Vidit, Shah, Paras, Costello, Brian A. , Pagliaro, Lance C. , Orme, Jacob J. , Brown, Jason R., Jang, Albert , Brown, Jason R. , Singh, Parminder , Grier, Abby L , Basourakos, Spyridon , Singh, Parminder , Zakharia, Yousef , Lucien, Fabrice , Orme, Jacob J , Brown, Jason R , Jang, Albert , Calaway, Adam , Karnes, R. Jeffrey , Sharma, Vidit, Shah, Paras

Mayo Clinic

Cancers | February 16, 2026 | Volume: 18 | Issue: 4 | Pages: 623

10.3390/cancers18040623 | PMID 41749876 Get It

Non-muscle-invasive bladder cancer (NMIBC) comprises approximately 75% of new bladder cancer cases and generally carries a favorable prognosis, yet high rates of recurrence and progression necessitate close surveillance with frequent cystoscopies and repeated transurethral resections. Upfront treatment for high-risk disease is typically Bacillus Calmette-Guérin (BCG), although combinations with immune checkpoint inhibitors have reported results. Patients with BCG-unresponsive, intolerant, or refractory disease represent a subset of patients with high risk of progression, with early radical cystectomy being the standard approach for this setting. Global BCG shortages and the substantial impact of cystectomy on quality of life underscore the need for therapeutic alternatives. Over the past decade, investigational trials in immunotherapy have expanded treatment options for BCG-unresponsive NMIBC with CIS, leading to FDA approval of intravesical nadofaragene firadenovec, nogapendekin alfa-inbakicept, and systemic pembrolizumab. This narrative review summarizes developments in intravesical and systemic immunotherapies for NMIBC, highlights ongoing trials, and addresses controversies in trial design, treatment sequencing, comparative efficacy, and safety.
Epigenetic Regulation of Higher-Order Chromatin Structure (HOCS) and Its Implication in Human Diseases
Ladel, Luisa, Sailo, Bethsebie, Das, Paromita, Tan, Wan Ying , Chhoda, Ankit , Tang, Haoyu, Ang-Olson, Olivia, He, Linda, John, Nithyla, Kratz, Jeremy D. , Sharma, Anup , Ahuja, Nita, Ang-Olson, Olivia , Kratz, Jeremy D , Lin, Ethan Samuel , Tang, Haoyu , Ahuja, Nita

Mayo Clinic

Cancers | February 2, 2026 | Volume: 18 | Issue: 3 | Pages: 483

10.3390/cancers18030483 | PMID 41681953 Get It

Higher-order chromatin structures (HOCS) are fundamental to genome organization, gene regulation, and cellular homeostasis. This review examines the epigenetic mechanisms shaping HOCS, including DNA methylation, histone modifications, chromatin remodeling, and RNA-based regulatory processes. We also discuss the role of architectural proteins in maintaining chromatin topology while allowing dynamic changes to chromatin structure, thereby influencing gene expression. Growing evidence indicates that disruptions in HOCS contribute to a diverse array of human diseases, including cancer, aging-related disorders, and congenital abnormalities, primarily through aberrant gene regulation. We further discuss the concept of distinct genomic areas, in which specific chromatin regions orchestrate three-dimensional (3D) genome dynamics, positioning them as potential biomarkers and therapeutic targets. By emphasizing chromatin architecture on a global scale rather than at the level of individual genes, this review underscores its emerging relevance to precision medicine. Finally, we synthesize current technical advances, outline future directions for leveraging chromatin topology in disease diagnosis and treatment, and highlight key biological insights to reshape our understanding of genome function.
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
Sinicrope, Frank A., Segovia, Diana, Sharma, Nalin , Alberts, Steven R. , Hardin, Aaron , Rich, Thereasa A. , Shi, Qian, Sinicrope, Frank A. , Shi, Qian , Sinicrope, Frank A , Rich, Thereasa , Shi, Qian , Alberts, Steven R , Hardin, Aaron

Mayo Clinic

Journal of Clinical Oncology | January 30, 2026 | Volume: 44 | Issue: 15 | Pages: 1401-1415

10.1200/jco-25-02086 | PMID 41616224 Get It

PURPOSE Detection of molecular residual disease using circulating tumor DNA (ctDNA) may enable postoperative risk stratification and guide adjuvant therapy. We evaluated the prognostic value of a tissue-free, epigenomic ctDNA assay in patients with stage III colon cancer (CC) enrolled in a phase III adjuvant chemotherapy trial. METHODS Plasma samples were collected after surgery and before adjuvant infusional fluorouracil, leucovorin, and oxaliplatin alone or combined with cetuximab. ctDNA was analyzed using a tissue-free assay; in ctDNA-positive patients, tumor fraction (TF) was quantified and genotyping was performed with a 739-gene panel. Associations with disease-free survival (DFS), time to recurrence (TTR), and overall survival (OS) were assessed using multivariable Cox models adjusted for covariates. RESULTS Among 2,260 evaluable patients, 461 (20.4%) were ctDNA-positive with significantly higher detection in advanced T-/N-stage, high-grade, obstruction/perforation, and BRAF V600E tumors. At a median follow-up of 6.1 years, ctDNA positivity was independently associated with shorter TTR (hazard ratio [HR], 5.96 [95% CI, 5.11 to 6.96]), DFS (HR, 5.03 [95% CI, 4.36 to 5.81]), and OS (HR, 4.45 [95% CI, 3.76 to 5.27]; all P < .0001). The 5-year DFS was 27.7% (95% CI, 23.8 to 32.2) v 77.1% (95% CI, 75.1 to 79.1) in ctDNA-positive versus ctDNA-negative patients, and adverse prognostic impact was greater in lower T/N stage, low-risk, and dMMR subsets (interaction P = .0012-.041). Among ctDNA-positive patients, TF was nearly double in those who recurred or died ( P = .0002) and stratified patients for TTR, DFS, and OS (all adjusted P < .002). Genotyping identified mutations in FLT1 (OR, 8.99) and PREX2 (OR, 7.73) genes that were most strongly associated with recurrence ( P < .03). CONCLUSION Evaluation of ctDNA in resected stage III CC using a tissue-free assay provided robust and independent prognostic value. Higher ctDNA burden, dMMR, and specific mutations defined poor prognostic groups among ctDNA-positive patients.
Abstract A038: Evaluation of Recurrent Stroke Risk and Anticoagulation Treatment Response among Phenotypically Similar Clusters of Patients with ESUS
Goicoechea, Elena Badillo, Conyers, Frank, Kerrigan, Deborah, Eklund, Kelsey , Yaghi, Shadi, Khasiyev, Farid, Melkumova, Emiliya , Glover, Patrick , Nahab, Fadi, Shahrivari, Mahan, Nedelcu, Simona , Liebeskind, D, Smith, M. D., Zha, Alicia , Kasab, Sami Al, Farooqui, Mudassir, Rojas-Soto, Diana , Aziz, Yasmin, Herpich, Franziska , Nguyen, Thanh N., Kam, Wayneho , Dumitrascu, Oana, Alvi, Muhammad , Krishnaiah, Balaji , Omran, Setareh Salehi , Linares, Guillermo , Singh, Eesha , Penckofer, Mary, Thon, Jesse, Mannion, Shani, Abbasi, Mehdi, Sharma, Richa, Siegler, James E. , Lineback, Christina , Kerrigan, Deborah , Yaghi, Shadi , Culbertson, Collin J , Jillella, Dinesh , Nour, Hassan Aboul , Sloane, Kelly L , Kasab, Sami Al , Farooqui, Mudassir , Aziz, Yasmin , Nguyen, Thanh N. , Penckofer, Mary , Thon, Jesse , Peter, Shani , Sharma, Richa

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.a038 Get It

Introduction: Embolic stroke of undetermined source (ESUS) is a clinical construct encompassing heterogenous possible mechanisms of incident stroke, potentially with variable responsiveness to anticoagulation and antiplatelet treatment. This study aims to identify differences in recurrent stroke risk based on phenotypic clusters in an ESUS population, and whether some clusters may benefit relatively more from anticoagulation over antiplatelet therapy. Methods: We identified patient phenotypes from a multicenter, retrospective cohort study of 1909 ESUS patients by dividing them into groups using Partitioning Around Medoids (PAM) with correlation-weighted Gower distance over 23 baseline demographic, clinical, laboratory, radiographic, and cardiac features. We confirmed optimal clustering at 3 groups. We assessed cluster associations with time to recurrent stroke using Kaplan-Meier survival analysis. We then employed a causal survival forest to estimate conditional average treatment effects (CATE) of anticoagulation versus antiplatelet therapy using the same baseline features as predictors with a 365-day horizon for restricted mean survival time differences. Finally, we used best linear projection to identify baseline features predictive of treatment effect and assessed whether effects differed significantly by cluster. Results: Cluster 1 (n=542) identified a low-risk, younger sample with minimal baseline disability and comorbidity burden. Cluster 2 (n=743) comprised a moderate-risk phenotype with intermediate comorbidity. Cluster 3 (n=626) represented the oldest and highest-risk phenotype. Kaplan-Meier analysis demonstrated significant differences in stroke-free survival across patient clusters (p < 0.001), where Cluster 1 experienced the lowest recurrent stroke rate and Cluster 3 had the highest. The clustering algorithm successfully identified clinically meaningful phenotypes with distinct risk profiles. While CATE varied across clusters, the differences were not statistically significant. Conclusion: In a multicenter ESUS population, we identified 3 distinct phenotypic clusters, each comprising nearly one-third of the sample and with a differential risk of recurrent stroke. Although cluster was not a significant effect modifier, substantial CATE variability by cluster was observed. Future clinical trials may consider evaluating secondary stroke prevention therapies among phenotypically similar patients who may respond differentially to novel therapies.
Abstract WP163: Predictors Of All-Cause Readmissions After Spinal Cord Infarctions: A Nationwide Analysis
Bawaneh, Saif, Asghar, Muhammad Roshan, Al-Salahat, Ali, Hall, Alexander, Sharma, Rohan, Bawaneh, Saif, Al‐Salahat, Ali , Hall, A

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp163 Get It

Introduction: Spinal cord infarction (SCI) is a rare but serious neurological condition that accounts for 1-2% of all ischemic strokes and can lead to significant disability. Despite its clinical importance, existing studies are limited by small sample sizes that lack national generalizability, and little is known about post-discharge events such as hospital readmissions. We aimed to evaluate factors associated with all-cause hospital readmissions among hospitalizations with primary diagnosis of SCI, utilizing the Nationwide Readmissions Database (NRD). Methods: NRD data were abstracted from 2016 to 2022 including all hospitalizations of adult patients (≥18 years) with a primary diagnosis of SCI. Multiple-predictor logistic regression models were estimated to assess the association of demographic and clinical variables with all-cause 90-day readmissions. We included specific comorbidities often used in comorbidity scoring systems and added conditions or complications that are known to be associated with SCI. Statistically significant covariates from the unadjusted model were retained in the multiple-predictor model. Odds ratios (OR) with associated 95% Confidence intervals (CI) and p-values were reported. Results: From 2016 to 2022, there were an estimated 3321 hospitalizations with a primary diagnosis of SCI, out of which 27% (95% CI: 24-30%) were readmitted within 90 days. Demographic factors that were associated with lower odds of readmission included private insurance (vs. Medicare) and high-income quartile (Fig. 1). [AH1] [AAs2] Clinical factors that were associated with increased odds of readmission included autonomic dysfunction (OR = 5.44, 95% CI: 1.86 to 15.94), renal disease (OR = 3.57, 95% CI: 1.83 to 6.96), liver disease (OR = 2.40, 95% CI: 1.34 to 4.32), full clinical associations shown in Figure 2. Conclusion: We identified several clinical and demographic factors that were significantly associated with increased all-cause readmissions after SCI hospitalizations. Autonomic dysfunction and renal disease were among the top predictors of readmissions. We uncovered socioeconomic disparities in readmissions rates following SCI. This data may assist vascular neurologists, physicians and healthcare administrators in reducing readmissions after SCI and addressing these disparities. Additionally, our results can guide future studies focusing on the management of this rare entity.